Head-to-head evidence
BPI-16350 vs Palbociclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
BPI-16350
Developed by Betta Pharmaceuticals Co.
NCT05433480 · Phase 3 · status unknown
This randomised, quadruple-blind, placebo-controlled trial in 274 women with HR-positive, HER2-negative advanced breast cancer reported median progression-free survival of 16.5 months with tibremciclib plus fulvestrant against 5.6 months with placebo plus fulvestrant, a hard clinical endpoint.
Palbociclib · Ibrance
Marketed by Pfizer
NCT01740427 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled phase 3 trial with 666 participants. Its primary clinical endpoint, investigator-assessed progression-free survival using RECIST criteria, was significantly improved with palbociclib plus letrozole (hazard ratio 0.576; p<0.000001), supporting a strong evidence grade.
Next expected readout: November 2026 · NCT02605486 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BPI-16350's landscape · Palbociclib's landscape